/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

Soleno Therapeutics Inc Share Price Today: Live Updates & Key Insights

Soleno Therapeutics Inc share price today is $36.5, up -5.92%. The stock opened at $38.5 against the previous close of $39.05, with an intraday high of $38.5 and low of $36.355.

Soleno Therapeutics Inc Share Price Chart

style
pb-0

Soleno Therapeutics Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

Soleno Therapeutics Inc Share Price Performance

$36.5 -0.0592(-5.92%) SLNO at 13 Mar 2026 03:15 PM Biotechnology
Lowest Today 36.355
Highest Today 38.5
Today’s Open 38.5
Prev. Close 39.05
52 Week High 90.32
52 Week Low 32.63
Day’s Range: Low 36.355 High 38.5
52-Week Range: Low 32.63 High 90.32
1 day return -
1 Week return -7.4
1 month return -1.23
3 month return -26.39
6 month return -28.16
1 year return -25.28
3 year return +1765.98
5 year return +47.63
10 year return -

Soleno Therapeutics Inc Institutional Holdings

FMR Inc 15.65

HHG PLC 11.73

T. Rowe Price Associates, Inc. 7.56

BlackRock Inc 6.76

Wellington Management Company LLP 6.44

Vanguard Group Inc 5.93

venBio Select Advisor LLC 5.62

State Street Corp 4.21

Vanguard Health Care Inv 3.83

Vanguard Total Stock Mkt Idx Inv 3.16

State Street® SPDR® S&P® Biotech ETF 3.09

Amvescap Plc. 2.91

T. Rowe Price US All-Cap Opp Eq Comp 2.56

Nantahala Capital Management, LLC 2.55

COMMODORE CAPITAL LP 2.32

Polar Capital Holdings PLC 2.31

BRAIDWELL LP 2.30

iShares Russell 2000 ETF 2.20

Woodline Partners LP 2.15

Geode Capital Management, LLC 2.10

Strategic Advisers Fidelity US TtlStk 2.08

Polar Capital Biotech S Inc 2.08

Fidelity Advisor Growth Opps M 2.02

Janus Henderson Global Life Sciences 1.94

Janus Henderson Global Life Sciences D 1.94

Millennium Management LLC 1.90

Fidelity OTC 1.84

T. Rowe Price All-Cap Opportunities Fund 1.79

Vivo Capital, LLC 1.73

Janus Henderson Glb Life Scn I2 USD 1.71

Janus Global Life Science AUSD 1.69

Franklin Resources Inc 1.62

Capital World Investors 1.60

JPMorgan Chase & Co 1.58

Janus Henderson Hrzn Biotec E2 USD 1.35

Fidelity Small Cap Growth 1.26

Janus Henderson Triton D 1.22

Janus Henderson US SMID Cap Growth 1.22

Vanguard Institutional Extnd Mkt Idx Tr 1.02

US Small-Cap Growth II Equity Comp 0.89

Soleno Therapeutics Inc Market Status

Strong Buy: 5

Buy: 3

Hold: 0

Sell: 0

Strong Sell: 0

Soleno Therapeutics Inc Fundamentals

Market Cap 2097.38 M

PB Ratio 4.4787

PE Ratio 100.1282

Enterprise Value 1763.01 M

Total Assets 563.83 M

Volume 1969588

Soleno Therapeutics Inc Company Financials

Annual Revenue FY25:190405000 190.4M, FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M

Annual Profit FY25:null 0.0M, FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M

Annual Net worth FY25:20890000 20.9M, FY23:-33178000 -33.2M, FY22:-20319000 -20.3M, FY21:-29561000 -29.6M, FY20:-15375000 -15.4M

Quarterly Revenue Q4/2025:91730000 91.7M, Q3/2025:66018000 66.0M, Q2/2025:32657000 32.7M, Q1/2025:0 0.0M, Q3/2024:0 0.0M

Quarterly Profit Q4/2025:null 0.0M, Q3/2025:64876999 64.9M, Q2/2025:31961000 32.0M, Q1/2025:null 0.0M, Q3/2024:null 0.0M

Quarterly Net worth Q4/2025:43358000 43.4M, Q3/2025:26013000 26.0M, Q2/2025:-4708000 -4.7M, Q1/2025:-43773000 -43.8M, Q3/2024:-76616000 -76.6M

About Soleno Therapeutics Inc & investment objective

Company Information Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.

Organisation Biotechnology

Employees 182

Industry Biotechnology

CEO Dr. Anish Bhatnagar M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow